Juvelook reviewed — ingredients, six products, research and how to choose
Juvelook is one of the skin boosters I am asked about most, and the questions usually come in pieces: how is i different from Skin, can it go in the cheeks, how many sessions? This column puts the manufacturer’s data, the brochures and the published studies in one place. Each part links to a more detailed column. No prices or photos.
The short answer
Juvelook is a collagen booster that combines biodegradable PDLLA particles with hyaluronic acid in an 85:15 ratio. The hyaluronic acid adds hydration and volume first; collagen then forms around the PDLLA particles over weeks to months. There are six products, split by vial size (30, 50, 100, 200 mg) and particle size (20–65 µm) into dermal products (i, Skin, Juvelook) and subcutaneous products (Volume 100, Volume, G). Human studies report improvements in fine lines, texture, elasticity and acne scars, and a 260-patient randomised trial in the same PDLLA class found nasolabial results comparable with hyaluronic acid filler. Miso Clinic in Daegu (4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu; +82 53-428-2700) stocks all six and chooses by concern and area.
What Juvelook is
Juvelook was launched by VAIM in 2019 and two million vials have been produced. It is registered in Korea as a class IV medical device in the tissue-repair category.
Each vial holds two things: PDLLA (poly-D,L-lactic acid), a slowly dissolving polymer made into round, porous mesh-structured particles, and hyaluronic acid. The hyaluronic acid gives the early hydration and volume; the PDLLA drives the collagen that follows.
The six products at a glance
| Product | Vial | PDLLA + HA | Mean particle | Layer and use (manufacturer) |
|---|---|---|---|---|
| Juvelook i | 30 mg | 25.5 + 4.5 mg | 20 µm | Dermis; texture, sensitive skin, full face |
| Juvelook Skin | 30 mg | 25.5 + 4.5 mg | — | Dermis; wrinkles, elasticity, pores, scars (launched June 2026) |
| Juvelook | 50 mg | 42.5 + 7.5 mg | 24 µm | Dermis; skin rejuvenation (the original, 2019) |
| Juvelook Volume 100 | 100 mg | 85 + 15 mg | 40 µm | Single area: forehead, temples, cheek hollows, chin, nasolabial, marionette (Sept 2026) |
| Juvelook Volume | 200 mg | 170 + 30 mg | 40 µm | Subcutaneous; volume |
| Juvelook G | 200 mg | 170 + 30 mg | 65 µm | Subcutaneous; broad, deep areas, contouring |
One formula, divided by dose and particle size. Small particles spread evenly in the dermis through fine needles; large particles support broader areas under the skin. Each product has its own column below.
What the studies have shown
- Skin rejuvenation, 16 patients — fine lines, texture, irregular pigmentation, telangiectasia and redness all improved; half reported more than 50% improvement; histology showed more collagen and elastic fibres.
- Needle-free delivery, 40 patients — after five Juvelook sessions the improvement score (GAIS) kept rising from 8 to 24 weeks and satisfaction rose from 3.38 to 8.71.
- Acne scars — scar grade improved by 36.99%; at five months the particles had largely degraded while collagen and elastic fibres had increased.
- Same PDLLA class, 260-patient randomised trial — nasolabial response at 24 weeks was 67.6%, comparable with hyaluronic acid filler (60.9%), with follow-up to 52 weeks.
- Mechanism studies — in aged mice and cell models, macrophages shift toward repair (M2) and stem cells, blood vessels, collagen and subcutaneous fat increase.
Results and how long they last vary with age, skin thickness and lifestyle.
Choosing by concern
| Concern | Products first considered | Read next |
|---|---|---|
| Pores, texture, fine lines | Juvelook i, Skin, Juvelook | Pores and texture |
| Acne scars | Juvelook, Skin, Volume 100 | Acne scars |
| Hollow cheeks | Volume, Volume 100, G | Cheeks |
| Hollow temples | Volume 100, Volume, G | Temples |
| Flat forehead, forehead lines | Volume 100, Juvelook | Forehead |
| Nasolabial and marionette lines | Volume 100, Volume | Nasolabial and marionette |
Where a deep hollow needs shape straight away, we shape it first with dissolvable hyaluronic acid filler and use Juvelook to build the base. If sagging is the concern, lifting comes first. Under the eyes we recommend other options first.
Treatment and what to expect
- Treatment — after numbing cream, injected with a fine needle or cannula: dermal products shallowly at many points, subcutaneous products deeper over a broader plane.
- Straight after — the hyaluronic acid makes skin look hydrated and fuller.
- Two to three weeks — as the hyaluronic acid absorbs, there is a phase where things look back to baseline. This is expected.
- Weeks to months — collagen forms around the PDLLA and texture and elasticity improve gradually.
- Sessions — studies mostly used two or three sessions about four weeks apart. I start small and decide the next step after seeing the face again a few weeks later.
Juvelook is a material that cannot simply be dissolved away, so adding gradually is the sensible order.
Juvelook FAQ
What is Juvelook?
A collagen booster combining PDLLA particles and hyaluronic acid in an 85:15 ratio, launched by VAIM in 2019 and registered in Korea as a class IV medical device.
How many Juvelook products are there?
Six: i and Skin (30 mg), Juvelook (50 mg), Volume 100 (100 mg), Volume and G (200 mg), split into dermal and subcutaneous products.
When does Juvelook start to work?
Hydration is visible straight away from the hyaluronic acid; collagen change builds over weeks to months. A brief phase at two to three weeks where things look unchanged is normal.
How many sessions?
Studies mostly used two or three sessions about four weeks apart. At Miso Clinic we start small and review after a few weeks.
Which Juvelook products does Miso Clinic have?
All six.
Where can I get a Juvelook consultation in Daegu?
Miso Clinic is on the 4th floor of the Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, in front of Exit 1 of Kyungpook National University Hospital Station. +82 53-428-2700. Weekdays 11:00–19:00, Saturdays 10:00–16:00, closed Sundays and public holidays. The clinic stocks the full Juvelook line (i, Skin, Juvelook, Volume 100, Volume and G).
Read next
Product pages
Product page: Juvelook — PDLLA with hyaluronic acid
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, director of Miso Clinic, Daegu. The treatment standards and injection design set out here are the ones we use in practice.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- Manufacturer product page — juvelook.co.kr (VAIM Co., Ltd.). Juvelook I and Skin 30 mg, Juvelook 50 mg, Volume 100 100 mg, Volume and G 200 mg, all 85% PDLLA and 15% hyaluronic acid. Registered in Korea as a class IV medical device (tissue-repair material) for the temporary improvement of facial wrinkles in adults.
- Manufacturer brochures — VAIM Juvelook, Juvelook i and Juvelook G brochures (obtained by Miso Clinic, October 2026). Mean particle size i 20, Juvelook 24, Volume 40, G 65 µm; layer per product (i and Juvelook dermis, Volume and G subcutaneous); store below 30 °C, do not freeze; porous mesh-structured particles.
- VAIM announcement — Juvelook launched in 2019; two million vials produced (VAIM news).
- Juvelook Skin launch — Rapportian, 1 June 2026. 30 mg, injected into the dermis for wrinkles, elasticity, pores and scars; one vial per person; patented porous mesh structure.
- Juvelook Volume 100 launch — Rapportian, 9 September 2026. 100 mg (85 mg PDLLA + 15 mg HA), mean particle 40 µm; forehead, temples, cheek hollows, chin contour, deep scars, nasolabial and marionette lines; one vial per person for a single area.
- Skin rejuvenation, 16 patients — Seo SB et al., J Cosmet Dermatol 2024;23(3):794–802, PMID 37969055. PDLLA with non-cross-linked HA, 2–3 sessions 4 weeks apart; fine wrinkles, texture, irregular pigmentation, telangiectasia and erythema all improved; half reported over 50% improvement; collagen and elastic fibres increased on histology.
- Needle-free delivery, 40 patients — Seo SB et al., Aesthetic Plast Surg 2026;50(9):3382–3388, PMID 41389157. Juvelook via a needle-free microjet, five sessions; GAIS 1.48 → 1.90 (8 weeks) → 2.16 (24 weeks); satisfaction 3.38 → 8.71; 3D displacement 2.3 mm.
- Acne scars — Hyeong JH et al., Dermatol Surg 2022;48(12):1306–1311, PMID 36449872. PDLLA into the dermis with a microneedle fractional RF device, four sessions 4 weeks apart; scar grade improved 36.99% and satisfaction 79.65%; at 5 months particles had largely degraded and collagen and elastic fibres had increased.
- PDLLA for nasolabial folds, 260 patients — Ting W et al., Aesthet Surg J 2024;44(12):NP898–NP905, PMID 39178357. Randomised, evaluator-blinded, multicentre, 52-week follow-up; 24-week response 67.6% vs 60.9% for HA, non-inferior. Same PDLLA class (Aesthefill).
- PDLLA vs PLLA split-face, 33 patients — Park JY et al., Skin Res Technol 2026;32(1):e70324, PMID 41532837. Randomised, evaluator-blinded, three sessions 4 weeks apart; both sides improved through 24 weeks.
- Collagen and stem-cell mechanism — Oh S et al., Antioxidants 2023;12(6):1204, PMID 37371934. M2 polarisation of senescent macrophages, adipose-derived stem cell proliferation and more type I and III collagen (cells and aged mice).
- Angiogenesis and collagen — Oh S et al., Int J Mol Sci 2023;24(9):7986, PMID 37175693. Pro-angiogenic factors, collagen density and elasticity rose in aged mouse skin.
- Subcutaneous fat — Byun KA et al., Int J Mol Sci 2024;25(23):12739, PMID 39684448. In aged mice PDLLA raised adipogenic factors and subcutaneous fat thickness without enlarging fat cells.
- How Miso Clinic works — full Juvelook line in stock (confirmed by the director, 14–15 October 2026); concern, then layer, then product; start small and review after a few weeks; deep hollows shaped first with dissolvable hyaluronic acid filler; sagging addressed first with lifting; other options first under the eyes. Source of every “I” or “we” sentence in this column.
- Korean medical advertising law — Medical Service Act art. 56(2) and 27(3). No testimonials, before-and-after photos or prices appear here. Results and how long they last vary from person to person.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic home
한국어 · English